Research
Molecular
Novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs) have insulin-sensitizing properties through a weight-independent action.
DACRAs may offer new treatment options for improving insulin sensitivity.
StrongSupportsmedium confidence
On the horizon are novel drug candidates like dual amylin and calcitonin receptor agonists (DACRAs), which elicit weight-loss, but also have insulin-sensitizing properties through a weight-independent action.
Why this rating
The abstract discusses the potential of new drug candidates in detail.
Source
Targeting the root cause of obesity-related comorbidities through weight independent and dependent actions on insulin sensitivity: Benefits of dual amylin and calcitonin receptor agonists
Anna Thorsø Larsen et al. · Biomedicine & Pharmacotherapy · 2025
reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →